<DOC>
	<DOC>NCT00850421</DOC>
	<brief_summary>The purposes of this study are to assess whether subjects treated with BOTOX will: 1. have a decrease in the frequency and intensity of migraine headaches 2. experience improvements in quality of life 3. experience a reduction in the frequency of health care services obtained.</brief_summary>
	<brief_title>Pilot Study of BOTOX for Migraine Headaches</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Subjects &gt; 18 years of age Subject has an established history of migraine headache, with or without aura, per IHS criteria (1.2.1 or 1.1), for at least 6 months prior to screening. Subject receives primary health care from Park Nicollet Health Services. Subject has received previous injections of botulinum toxin of any serotype for any reason, within the 6 months prior to study participation. Additional eligibility will be discussed at point of contact</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>migraine headache</keyword>
	<keyword>Botulinum Toxin Type A</keyword>
	<keyword>BOTOX</keyword>
	<keyword>BTX-A</keyword>
</DOC>